Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Diazepam for Alcohol Withdrawal Syndrome
NCT03877120Phase 4Completed
- Sponsor
- Centro Médico Nacional La Raza
- Start
- Nov 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dexmedetomidine in alcohol withdrawal syndrome (AWS), sponsored by Centro Médico Nacional La Raza. Primary endpoints: Clinical Institute Withdrawal Assessment for Alcohol at 10 days and Average Diazepam Received at 10 days. Started Nov 2017; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
alcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on NCT03877120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03877120.